IRadimed Forecasts Q1 FY24 Revenue of $17M-$17.3M, With Adjusted EPS Of $0.33-$0.35 Compared To Consensus Of $16.50M And $0.32, Respectively
Portfolio Pulse from Benzinga Newsdesk
IRadimed projects its Q1 FY24 revenue to be between $17M-$17.3M and adjusted EPS to range from $0.33-$0.35, surpassing the consensus estimates of $16.50M in revenue and $0.32 in EPS.
February 08, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IRadimed forecasts higher Q1 FY24 revenue and EPS than consensus estimates, indicating a positive outlook.
IRadimed's projection of higher revenue and EPS than consensus estimates for Q1 FY24 suggests the company is performing better than expected. This positive outlook is likely to instill confidence in investors, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100